Xenetic Biosciences (XBIO) Competitors $4.33 +0.13 (+3.19%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsOwnershipSEC FilingsShort InterestTrends XBIO vs. GDTC, IBIO, CTXR, LSB, LGVN, ATHE, ENLV, HOOK, LPCN, and EQShould you be buying Xenetic Biosciences stock or one of its competitors? The main competitors of Xenetic Biosciences include CytoMed Therapeutics (GDTC), iBio (IBIO), Citius Pharmaceuticals (CTXR), Lakeshore Biopharma (LSB), Longeveron (LGVN), Alterity Therapeutics (ATHE), Enlivex Therapeutics (ENLV), Hookipa Pharma (HOOK), Lipocine (LPCN), and Equillium (EQ). These companies are all part of the "pharmaceutical preparations" industry. Xenetic Biosciences vs. CytoMed Therapeutics iBio Citius Pharmaceuticals Lakeshore Biopharma Longeveron Alterity Therapeutics Enlivex Therapeutics Hookipa Pharma Lipocine Equillium Xenetic Biosciences (NASDAQ:XBIO) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, community ranking, media sentiment, institutional ownership and valuation. Which has more volatility and risk, XBIO or GDTC? Xenetic Biosciences has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500. Comparatively, CytoMed Therapeutics has a beta of -0.85, meaning that its stock price is 185% less volatile than the S&P 500. Does the MarketBeat Community prefer XBIO or GDTC? Xenetic Biosciences received 170 more outperform votes than CytoMed Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CytoMed Therapeutics an outperform vote while only 67.44% of users gave Xenetic Biosciences an outperform vote. CompanyUnderperformOutperformXenetic BiosciencesOutperform Votes17467.44% Underperform Votes8432.56% CytoMed TherapeuticsOutperform Votes4100.00% Underperform VotesNo Votes Does the media favor XBIO or GDTC? In the previous week, Xenetic Biosciences and Xenetic Biosciences both had 2 articles in the media. Xenetic Biosciences' average media sentiment score of 0.44 equaled CytoMed Therapeutics'average media sentiment score. Company Overall Sentiment Xenetic Biosciences Neutral CytoMed Therapeutics Neutral Is XBIO or GDTC more profitable? CytoMed Therapeutics has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -161.63%. CytoMed Therapeutics' return on equity of 0.00% beat Xenetic Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Xenetic Biosciences-161.63% -49.51% -43.99% CytoMed Therapeutics N/A N/A N/A Do insiders & institutionals believe in XBIO or GDTC? 15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 14.7% of Xenetic Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend XBIO or GDTC? CytoMed Therapeutics has a consensus price target of $5.00, indicating a potential upside of 94.93%. Given CytoMed Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytoMed Therapeutics is more favorable than Xenetic Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00CytoMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, XBIO or GDTC? CytoMed Therapeutics has lower revenue, but higher earnings than Xenetic Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXenetic Biosciences$2.54M2.51-$4.14M-$2.66-1.56CytoMed TherapeuticsN/AN/A-$3.13MN/AN/A SummaryCytoMed Therapeutics beats Xenetic Biosciences on 8 of the 13 factors compared between the two stocks. Get Xenetic Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XBIO vs. The Competition Export to ExcelMetricXenetic BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.38M$6.92B$5.61B$9.14BDividend YieldN/A2.95%5.36%3.98%P/E Ratio-1.5610.1189.6917.66Price / Sales2.51351.361,219.4081.09Price / CashN/A65.4844.3437.71Price / Book0.655.335.134.73Net Income-$4.14M$157.56M$118.85M$225.42M7 Day Performance-2.03%2.83%1.87%-0.44%1 Month Performance2.35%2.84%7.96%3.57%1 Year Performance17.42%8.37%26.70%19.20% Xenetic Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XBIOXenetic Biosciences1.4277 of 5 stars$4.15-1.3%N/A+14.9%$6.38M$2.54M-1.564Short Interest ↑GDTCCytoMed Therapeutics1.7826 of 5 stars$2.38-0.4%$5.00+110.1%-29.7%$26.04MN/A0.00N/AShort Interest ↑Gap DownIBIOiBio1.4487 of 5 stars$2.83-0.4%$4.30+51.9%N/A$25.89M$220,000.000.00100CTXRCitius Pharmaceuticals3.1216 of 5 stars$3.30+1.2%$54.50+1,551.5%-83.3%$25.51MN/A-0.5520Short Interest ↑LSBLakeshore Biopharma1.6314 of 5 stars$2.72+15.7%N/AN/A$25.32M$80.82M0.00773Short Interest ↓LGVNLongeveron3.1051 of 5 stars$1.70-3.4%$8.67+409.8%-77.1%$25.23M$710,000.00-0.2723Positive NewsATHEAlterity Therapeutics3.0437 of 5 stars$3.42+1.8%$6.00+75.4%+57.9%$24.97MN/A0.0010Upcoming EarningsAnalyst ForecastShort Interest ↓News CoverageGap UpENLVEnlivex Therapeutics3.7809 of 5 stars$1.13-1.7%$9.50+740.7%-56.3%$24.19MN/A-1.1570Short Interest ↓HOOKHookipa Pharma2.9735 of 5 stars$1.95+0.5%$23.00+1,079.5%-68.4%$23.52M$20.13M-0.5256Short Interest ↑Gap DownLPCNLipocine2.6428 of 5 stars$4.37-1.8%$10.00+128.8%+14.7%$23.37M$7.92M-5.7510EQEquillium3.0802 of 5 stars$0.64-8.0%$5.00+676.5%-23.6%$22.81M$36.08M-4.6040Short Interest ↓Gap Down Related Companies and Tools Related Companies GDTC Competitors IBIO Competitors CTXR Competitors LSB Competitors LGVN Competitors ATHE Competitors ENLV Competitors HOOK Competitors LPCN Competitors EQ Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XBIO) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredTrillion-Dollar Crypto PlayPotential $20-trillion opportunity? Put $500 into THIS AI Coin for 2025… Crypto 101 Media | SponsoredTrump’s back in the oval office. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. And he says 2025 could be...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenetic Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
